{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002981","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.111477+00:00","generated_at":"2026-05-22T04:36:55.616715+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus Q1 net income $15.2M; soquelitinib atopic derm cohort 3 EASI −71.1% vs placebo −42.1%","bullets":["Net income of $15.2M included $25.1M gain on warrant liability; R&D spend $7.5M vs $4.1M YoY.","Cash $44.2M at Mar 31; May warrant exercises added ~$31.3M, extending runway into Q4 2026.","Phase 1 atopic derm: cohort 3 (200 mg BID) achieved 71.1% mean EASI reduction vs 42.1% placebo; combined active vs placebo p=0.03.","No placebo patient achieved IGA 0/1 or EASI 75; soquelitinib well tolerated with no DLTs.","Protocol amended: replace cohort 4 with 24 patients (1:1 active/placebo) at 200 mg BID for 8 weeks; Phase 2 to start by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002981","json":"https://secwatch.observer/filing/0001171843-25-002981.json","markdown":"https://secwatch.observer/filing/0001171843-25-002981.md","text":"https://secwatch.observer/filing/0001171843-25-002981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/0001171843-25-002981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/f8k_050825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:36:55.616715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}